REGISTER RECORD · ctis
2022-502046-28-00
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo® Versus Placebo in Combination with Phesgo® as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA‑Mutated HER2‑Positive Locally Advanced or Metastatic Breast Cancer
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | The register records no status for this entry. |
|---|---|
| Register last updated | 2026-06-23 |
| Retrieved by this site | 2026-10-03 |
| Source | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502046-28-00 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.